Intracranial germ cell tumors are among the rarest and most perplexing malignancies of the central nervous system. They arise from primitive germ cells that, during embryonic development, fail to complete their migration and instead settle in the brain, most often near the pineal or sellar regions. Although these tumors respond well to modern radiotherapy and chemotherapy in most patients, a small subset follows a relentlessly recurrent course, relapsing again and again despite surgery, radiation, and successive lines of chemotherapy. A new retrospective study from Sanbo Brain Hospital in Beijing, published in Frontiers in Oncology, now offers one of the most detailed clinical portraits yet of this difficult-to-treat population, documenting what happens when these brain tumors recur three or more times.
The research team, led by Chuan Zhao and Junping Zhang of the Department of Neurosurgery and Neuro-oncology at Sanbo Brain Hospital, Capital Medical University, analyzed the records of 49 patients treated between 2016 and 2023 who had experienced at least three recurrences of an intracranial germ cell tumor. The cohort was overwhelmingly male, with 39 boys and men (79.6 percent) and 10 girls and women (20.4 percent), reflecting the known male predominance of this tumor type. The mean age at initial presentation was just 13.29 years, with a standard deviation of 5.99 years, underscoring that these are overwhelmingly diseases of children and adolescents. Histologically, 13 patients (26.5 percent) had pure germinomas, while 36 patients (73.5 percent) had non-germinomatous germ cell tumors, or NGGCTs, a heterogeneous group that includes teratomas, yolk sac tumors, choriocarcinomas, and embryonal carcinomas.
The number of recurrences ranged from 3 to 11, with most patients (61.2 percent) experiencing exactly three relapses. Ten patients (20.4 percent) relapsed four times, four patients (8.2 percent) five times, and five patients relapsed six or more times, including one child who endured an extraordinary 11 recurrences over more than a decade of treatment. The study recorded treatment modalities at initial diagnosis and at each recurrence, including surgical interventions, radiation therapy, chemotherapy regimens, and any associated adverse events. Recurrence was defined as the reappearance or progression of tumor after initial response, confirmed by new or enlarged lesions on contrast-enhanced MRI, histological confirmation of viable tumor, or a sustained rise in serum alpha-fetoprotein (AFP) or human chorionic gonadotropin (HCG) above the upper limit of normal.
One of the most striking findings of the study concerns the temporal pattern of relapse. The researchers defined progression-free survival (PFS) intervals between successive recurrences: PFS1 as the time from initial diagnosis to first recurrence, PFS2 as the interval from first to second recurrence, and PFS3 as the interval from second to third recurrence. For pure germinomas, the median PFS1 was 25.03 months, but the median PFS2 dropped to 14.16 months, a statistically significant shortening (P = 0.0286). The Friedman test, a non-parametric statistical test for detecting differences in treatments across multiple test attempts, revealed a highly significant decreasing trend in PFS intervals with successive recurrences in germinomas (P < 0.0001). In other words, once a germinoma begins to relapse, it tends to do so faster and faster.
The same pattern held for NGGCTs, but with even shorter intervals. The median PFS1 for NGGCT patients was 9.05 months, the median PFS2 was 5.61 months (P = 0.0428), and the median PFS3 was just 4.02 months (P < 0.0001). The Friedman test again demonstrated a statistically significant shortening of PFS intervals with successive relapses (P = 0.0092). This accelerating rhythm of recurrence is a critical clinical observation, because it suggests that multiply recurrent germ cell tumors become increasingly resistant to conventional salvage therapies over time, leaving clinicians with a progressively narrowing therapeutic window.
Overall survival told a similarly sobering story. The overall survival of germinoma patients was significantly better than that of NGGCT patients (P = 0.0019), consistent with the established biological distinction between these two tumor types. Germinomas are exquisitely sensitive to radiotherapy and chemotherapy and generally carry an excellent prognosis, with 5-year survival rates in the broader literature ranging from 70 to 90 percent. NGGCTs, by contrast, have variable and often less favorable outcomes due to their diverse histology and treatment responses. Yet the presence of 13 multiply recurrent germinoma patients in this cohort, accounting for 26.5 percent of the sample, is itself remarkable, because germinomas typically account for about two-thirds of intracranial germ cell tumors and rarely relapse after standard therapy. This suggests that a subset of germinomas may be intrinsically resistant to conventional radiotherapy and chemotherapy, a finding that the authors argue warrants exploration of alternative therapeutic strategies such as immunotherapy or targeted therapy guided by specific molecular characteristics.
Multivariate Cox proportional hazards regression analysis, performed to identify factors associated with progression-free survival before the first recurrence, revealed no statistically significant predictors in the germinoma subgroup for age at diagnosis, sex, tumor location, presence of dissemination, radiotherapy, chemotherapy, resection, or biomarkers. In the NGGCT subgroup, however, chemotherapy at initial diagnosis emerged as independently associated with shorter PFS1 (P < 0.001). The authors are careful to note that this result likely reflects confounding by indication rather than a detrimental effect of chemotherapy itself: in clinical practice, chemotherapy for NGGCT is rarely used alone but rather in conjunction with radiotherapy, and the majority of patients (69.4 percent, 25 of 36) underwent multimodal therapy. More intensive chemotherapy was likely selected for patients with higher-risk disease features at presentation, underscoring the importance of risk-adapted, multimodality therapy as established in protocols like SIOP-CNS-GCT-96.
The treatment trajectories documented in the study illustrate a shifting paradigm in the management of multiply recurrent disease. While initial management is multimodal, combining surgery, radiation, and chemotherapy, upon multiple recurrences the therapeutic arsenal narrows predominantly to systemic chemotherapy, as the feasibility of repeat surgery and radiotherapy diminishes due to cumulative toxicity and anatomical constraints. In the germinoma subgroup, all 13 patients received radiotherapy as part of primary treatment, but by the third recurrence only 4 of 11 patients treated received radiotherapy, while 11 of 11 received chemotherapy. Similarly, in the NGGCT subgroup, 22 of 36 patients underwent surgery at initial diagnosis, but by the second recurrence only 8 did, while 29 of 36 received chemotherapy. One patient received immunotherapy at the third recurrence of a germinoma, and one NGGCT patient received targeted therapy at the second recurrence, hinting at emerging salvage options beyond conventional cytotoxic agents.
The individual case histories in the study are sobering illustrations of the human cost of multiply recurrent disease. One 9-year-old girl presented in 2013 with a suprasellar mass and endured five recurrences involving intraspinal and intracranial dissemination over eight years, treated with repeated BEP (cisplatin, etoposide, bleomycin), spinal radiotherapy, ifosfamide-carboplatin-etoposide, pemetrexed-cisplatin with Endostar, whole-brain plus local radiotherapy, and temozolomide with anlotinib, before dying of disease progression in 2021 with an overall survival of 8 years and 1 month. A 16-year-old boy with a pineal germinoma experienced five recurrences with extensive intraspinal, ventricular, brainstem, and cerebellar dissemination, treated with multiple chemotherapy regimens and repeated radiotherapy; at last follow-up in 2023 he was alive without recurrence but had impaired balance and memory. A third patient, a boy with an NGGCT containing mature teratoma components, endured 11 recurrences over more than a decade, treated with surgery, whole-spinal and local radiotherapy, gamma knife radiosurgery, multiple chemotherapy protocols, and apatinib, before eventually dying of disease progression.
The authors acknowledge several limitations of their work. It is a retrospective study rather than a randomized trial, it lacks molecular-level and mechanistic investigations, and the cases were treated at multiple hospitals with various confounding factors, although this also reflects the real-world situation of repeatedly recurrent germ cell tumors. The absence of a non-recurrent control group and the relatively small sample size limit the ability to detect factors uniquely predictive of multiple relapses; based on the observed effect sizes, approximately 120 to 150 patients would be required for 80 percent statistical power. The lack of centralized pathology review and molecular profiling data prevents exploration of the biological determinants of aggressive, recurrent disease. The authors call for future multicenter prospective studies with matched controls, centralized pathology review, and molecular profiling, including methylation subtyping and driver gene analysis, to identify biological subtypes underlying the multiply recurrent phenotype. For now, the study provides a sobering quantitative foundation for understanding what happens when these rare brain tumors refuse to stay away: the intervals between relapses shorten with each successive recurrence, management increasingly relies on systemic chemotherapy as local modalities become less feasible, and NGGCT patients face significantly worse overall survival than those with germinomas.
Subject of Research: A retrospective study: multiply recurrent intracranial germ cell tumors
Article Title: A retrospective study: multiply recurrent intracranial germ cell tumors
Article References: Zhao, C., Ge, J., Li, C., Zhao, C., Qi, S., Xue, F., Zhang, J., & Zhang, J. (2026). A retrospective study: multiply recurrent intracranial germ cell tumors. Frontiers in Oncology, 16, Article 1962932. https://doi.org/10.3389/fonc.2026.1962932
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1962932
Keywords: neuro-oncology, germ cell tumors, brain tumor recurrence, pediatric cancer, chemotherapy, cancer research, retrospective, multiply, recurrent, intracranial, germ, cell
News Source: Nathaniel Bowman. (October 19, 2026). When Brain Tumors Keep Coming Back: Recurrence Intervals Shorten With Each Relapse. Scienmag.
